Smart MR imaging agents relevant to potential neurologic applications

American Journal of Neuroradiology

Volumn 31, Issue 3, 2010, Pages 401-409

  Bonnet, C S ^a   Tóth, Éva ^a  

^a CENTRE DE BIOPHYSIQUE MOLÉCULAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CARBONATE DEHYDRATASE INHIBITOR; COPPER; GADOLINIUM; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE PHENANTROLINE FE 3; GADOTERATE MEGLUMINE; GADOTERIC ACID; IRON; METAL ION; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; SULFONAMIDE; UNCLASSIFIED DRUG; ZINC;

CARDIOVASCULAR DISEASE; CHEMISTRY; ENZYME ACTIVITY; HEART INFARCTION; HUMAN; HYPOXIA; MOLECULAR IMAGING; MOLECULAR PROBE; NEUROBIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATION REDUCTION REACTION; OXYGENATION; PH; POSITRON EMISSION TOMOGRAPHY; REVIEW;

BRAIN DISEASES; CONTRAST MEDIA; HETEROCYCLIC COMPOUNDS; HUMANS; MAGNETIC RESONANCE IMAGING; NEUROLOGY; ORGANOMETALLIC COMPOUNDS;

EID: 77949511304     PISSN: 01956108     EISSN: None     Source Type: Journal    
DOI: 10.3174/ajnr.A1753     Document Type: Review

References (82)

1. Merbach AE, Toth E. The Chemistry of Contrast Agents in Medical Magnetic Resonance Imaging. Chichester, UK: John Wiley & Sons; 2001
2. Caravan P, Ellison JJ, McMurry TJ, et al. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev 1999;99: 2293-352
3. Allen MJ, Meade TJ. Magnetic resonance contrast agents for medical and molecular imaging. Met Ions Biol Syst 2004;42:1-38
4. Aime S, Delli Castelli D, Terreno E. Novel pH-reporter MRI contrast agents. Angew Chem Int Ed Engl 2002;41:4334-36
5. Zhang S, Winter P, Wu K, et al. A novel europium(III)-based MRI contrast agent. J Am Chem Soc 2001;123:1517-18
6. Woods M, Woessner DE, Sherry AD. Paramagnetic lanthanide complexes as PARACEST agents for medical imaging. Chem Soc Rev 2006;35:500-11
7. Woessner DE, Zhang S, Merritt ME, et al. Numerical solution of the Bloch equations provides insights into the optimum design of PARACEST agents for MRI. Magn Reson Med 2005;53:790-99
8. Sherry AD, Woods M. Chemical exchange saturation transfer contrast agents for magnetic resonance imaging. Annu Rev Biomed Eng 2008;10:391-411
9. Hammoud DA, Hoffman JM, Pomer MG. Molecular neuroimaging: from conventional to emerging techniques. Radiology 2007;245:21-42
10. Jasanoff A. MRI contrast agents for functional molecular imaging of brain activity. Curr Op Neurobiol 2007;17:593-600
11. Que LE, DomailleDW,Chang CJ, Metals in neurobiology: probing their chemistry and biology with molecular imaging. Chem Rev 2008;108:1517-49
12. Logothetis NK. What we can do and what we cannot do with fMRI. Nature 2008;453:869-78
13. 2+ influx into dendritic tufts of layer 2/3 neocortical pyramidal neurons in vitro and in vivo. J Neurosci 2003;23:8558-67
14. Kerr JND, Greenberg D, Helmchen F. From the cover: imaging input and output of neocortical networks in vivo. Proc Natl Acad Sci U S A 2005;102: 14063-68
15. Ohki K, Chung S, Ch'ng YH, et al. Functional imaging with cellular resolution reveals precise micro-architecture in visual cortex. Nature 2005;433:597- 603. Epub 2005 Jan 19
16. Somjen GG. Ions in the Brain: Normal Function, Seizures, and Stroke. Oxford, UK: Oxford University Press; 2004
17. Koller CW. Neuroprotective therapy for Parkinson's disease. Exp Neurol 1997;144:24-28
18. 2+-dependent depolarization of rat and human mitochondria: relevance to Huntington's disease. Arch Biochem Biophys 2003;410:1-6
19. 2+ currents in mice dorsal root ganglion neurons. Neurosci Lett 1997;235:69-72
20. Jimerson DC, Post RM, Carman JS, et al. CSF calcium: clinical correlates in affective illness and schizophrenia. Biol Psychiatry 1979;14:37-51
21. Yarlagadda A. Role of calcium regulation in pathophysiology model of schizophrenia and possible interventions. Med Hypotheses 2002;58:182-86
22. Gailly P. New aspects of calcium signaling in skeletal muscle cells: implications in Duchenne muscular dystrophy. Biochim Biophys Acta 2002;1600: 38-44
23. Lin YJ, Koretsky AP. Manganese ion enhances T1-weighted MRI during brain activation: an approach to direct imaging of brain function. Magn Reson Med 1997;38:378-88
24. Koretsky AP, Silva AC. Manganese-enhanced magnetic resonance imaging (MEMRI). NMR Biomed 2004;17:527-31
25. Atanasijevic T, Shusteff M, Fam P, et al. Calcium-sensitive MRI contrast agents based on superparamagnetic iron oxide nanoparticles and calmodulin. Proc Natl Acad Sci U S A 2006;103:14707-712
26. Shapiro MG, Atanasijevic T, Faas H, et al. Dynamic imaging with MRI contrast agents: quantitative considerations. Magn Res Imaging 2006;24:449-62
27. Li W, Fraser SE, Meade TJ. A calcium-sensitive magnetic resonance imaging contrast agent. J Am Chem Soc 1999;12:1413-14
28. 3+ complexes. J Biol Inorg Chem 2008;13:35-46. Epub 2007 Sep 15
29. Mishra A, Fousková P, Angelovski G, et al. Facile synthesis and relaxation properties of novel bispolyazamacrocyclic Gd(3+) complexes: an attempt towards calcium-sensitive MRI contrast agents. Inorg Chem 2008;47:1370-81. Epub 2008 Mar 28
30. Angelovski G, Fousková P, Mamedov I, et al. Smart MRI agents sensing extracellular calcium fluctuations. Chembiochem 2008;9:1729-34
31. Dhingra K, Maier ME, Beyerlein M, et al. Synthesis and characterization of a smart contrast agent sensitive to calcium. Chem Commun (Camb) 2008;3444-46. Epub 2008 Jun 4
32. Faller P, Hureau C. Bioinorganic chemistry of copper and zinc ions coordinated to amyloid-beta peptide. Dalton Trans 2009:1080 -94. Epub 2008 Nov 26
33. Hanaoka K, Kikuchi K, Urano Y, et al. Selective sensing of zinc ions with a novel magnetic resonance imaging contrast agent. J Chem Soc Perkin Trans 2 2001:1840
34. Hanaoka K, Kikuchi K, Urano Y, et al. Design and synthesis of a novel magnetic resonance imaging contrast agent for selective sensing of zinc ion. Chem Biol 2002;9:1027-32
35. Major JL, Boiteau RM, Meade TJ. Mechanisms of ZnII-activated resonance imaging agents. Inorg Chem 2008;47:10788 -95. Epub 2008 Oct 18
36. Major JL, Parigi G, Luchinat C, et al. The synthesis and in vitro testing of a zinc-activatedMRIcontrast agent. Proc Natl Acad SciUSA2007;104:13881-86
37. Trokowski R, Ren J, Kalman FK, et al. Selective sensing of zinc ions with a PARACEST contrast agent. Angew Chem Int Ed Engl 2005;44:6920-23
38. Paris J, Gameiro C, Humblet V, et al. Auto-assembling of ditopic macrocyclic lanthanide chelates with transition-metal ions: rigid multimetallic high relaxivity contrast agents for magnetic resonance imaging. Inorg Chem 2006;45: 5092-102
39. Livramento JB, Toth E, Sour A, et al. High relaxivity confined to a small molecular space: a metallostar-based, potential MRI contrast agent. Angew Chem Int Ed Engl 2005;44:1480-84
40. Livramento JB, Sour A, Borel A, et al. A starburst-shaped heterometallic compound incorporating six densely packed Gd(3+) ions. Chemistry 2006;12: 989-1003
41. Livramento JB, Weidensteiner C, Prata MI, et al. First in vivo MRI assessment of a self-assembled metallostar compound endowed with a remarkable high field relaxivity. Contrast Media Mol Imaging 2006;1:30-39
42. Parac-Vogt TN, Vander Elst L, Kimpe K, et al. Pharmacokinetic and in vivo evaluation of a self-assembled gadolinium(III)-iron(II) contrast agent with high relaxivity. Contrast Med Mol Imaging 2006;1:267-78
43. Jacques V, Desreux JF. New classes of MRI contrast agents. Top Curr Chem 2002;221:125-64
44. Aime S, Botta M, Fasano M, et al. Paramagnetic GdIII-FeIII heterobimetallic complexes of DTPA-bis-salicylamide. Spectrochimica Acta 1993;9:1315-22
45. Gaggelli E, Kozlowsky H, Valensin D, et al. Copper homeostasis and neurodegenerative disorders (Alzheimer's prion, and Parkinson's diseases and amyotrophic lateral sclerosis). Chem Rev 2006;106:1995-2044
46. Que EL, Chang CJ. A smart magnetic resonance contrast agent for selective copper sensing. J Am Chem Soc 2006;128:15942-43
47. Gillies RJ, Raghunand N, Karczmar GS, et al. MRI of the tumor microenvironment. J Magn Reson Imaging 2002;16:430-50
48. Chesler M. Regulation and modulation of pH in the brain. Physiol Rev 2003;83:1183-221
49. Kalman FK, Woods M, Caravan P, et al. Potentiometric and relaxometric properties of a gadolinium-based MRI contrast agent for sensing tissue pH. Inorg Chem 2007;46:5260-70
50. Aime S, Crich SG, Gianolio E, et al. High sensitivity lanthanide(III) based probes for MR-medical imaging. Coord Chem Rev 2006;250:1562-79
51. Mikawa M, Miwa N, Brautigam M, et al. A pH-sensitive contrast agent for functional magnetic resonance imaging (MRI). Chem Lett 1998;7:693-94
52. Aime S, Crich SG, Botta M, et al. A macromolecular Gd(III) complex as pHresponsive relaxometric probe for MRI applications. Chem Commun 1999:1577-78
53. Lowe MP, Parker D, Reany O, et al. pH-dependent modulation of relaxivity and luminescence in macrocyclic gadolinium and europium complexes based on reversible intramolecular sulfonamide ligation. J Am Chem Soc 2001;123: 7601-09
54. Hovland R, Glogard C, Aasen AJ, et al. Gadolinium DO3A derivatives mimicking phospholipids; preparation and in vitro evaluation as pH responsive MRI contrast agents. J Chem Soc Perkin Trans 2 2001;6:929-33
55. Toth E, Bolskar RD, Borel A, et al. Water-soluble gadofullerenes: toward highrelaxivity, pH-responsive MRI contrast agents. J Am Chem Soc 2005;127:799-805
56. Zhang S, Wu K, Sherry AD. A novel pH-sensitive MRI contrast agent. Angew Chem Int Ed Engl 1999;38:3192-94
57. Raghunand N, Howison C, Sherry AD, et al. Renal and systemic pH imaging by contrast-enhanced MRI. Magn Reson Med 2003;49:249-57
58. Garcia-Martin ML, Martinez GV, Raghunand N, et al. High-resolution pH(e) imaging of rat glioma using pH-dependent relaxivity. Magn Reson Med 2006;55:309-15
59. Ali MM, Woods M, Caravan P, et al. Synthesis and relaxometric studies of a dendrimer-based pH-responsive MRI contrast agent. Chemistry 2008;14: 7250-58
60. Ward KM, Balaban RS. Determination of pH using water protons and chemical exchange dependent saturation transfer (CEST). Magn Reson Med 2000;44:799-802
61. Aime S, Barge A, Delli Castelli D, et al. Paramagnetic lanthanide(III) complexes as pH-sensitive chemical exchange saturation transfer (CEST) contrast agents for MRI applications. Magn Reson Med 2002;47:639-48
62. Terreno E, Delli Castelli D, Cravotto G, et al. Ln(III)-DOTAMGly complexes: a versatile series to assess the determinants of the efficacy of paramagnetic chemical exchange saturation transfer agents for magnetic resonance imaging applications Invest Radiol 2004;39:235-43
63. Moats RA, Fraser SE, Meade TJ. A "smart" magnetic resonance imaging agent that reports on specific enzymatic activity. Angew Chem Int Ed Engl 1997;36: 726-28
64. Louie AY,HüberMM,Ahresn ET, et al. In vivo visualization of gene expression using magnetic resonance imaging. Nat Biotechnol 2000;18:321-25
65. Anelli PL, Bertini I, Fragai M, et al. Sulfonamide-functionalized gadolinium DTPA complexes as possible contrast agents for MRI: a relaxometric investigation. Eur J Inorg Chem 2000:625-30
66. Nivorozhkin AL, Kolodziej AF, Caravan P, et al. Enzyme-activated Gd(III) magnetic resonance imaging contrast agents with a prominent receptor-induced magnetization enhancement. Angew Chem Int Ed Engl 2001;40:2903-06
67. Lauffer RB, McMurry TJ, Dunham SO, et al. Epix Medical Inc. Bioactivated diagnostic imaging contrast agents. Patent publication number WO9736619. October 9, 1997
68. Mazooz G, Mehlman T, Lai TS, et al. Development of magnetic resonance imaging contrast material for in vivo mapping of tissue transglutaminase activity. Cancer Res 2005;65:1369-75
69. Shiftan L, Israely T, Cohen M, et al. Magnetic resonance imaging visualization of hyaluronidase in ovarian carcinoma. Cancer Res 2005;65:10316-23
70. Chen JW, Pham W, Weissleder R, et al. Human myeloperoxidase: a potential target for molecular MR imaging in atherosclerosis. Magn. Reson Med 2004;52:1021-28
71. Querol M, Chen JW, Weissleder R, et al. DTPA-bisamide-based MR sensor agents for peroxidase imaging. Org Lett 2005;7:1719-22
72. Duimstra JA, Femia FJ, Meade TJ. A gadolinium chelate for detection of betaglucuronidase: a self-immolative approach. J AmChem Soc 2005;127:12847-55
73. Yoo B, Pagel MD. A PARACEST MRI contrast agent to detect enzyme activity. J Am Chem Soc 2006;128:14032-33
74. Yoo B, Raam MS, Rosenblum RM, et al. Enzyme-responsive PARACEST MRI contrast agents: new biomedical imaging approach for studies of the proteasome. Contrast Media Mol Imaging 2007;2:189-98
75. Chauvin T, Durand P, Bernier M, et al. Detection of enzymatic activity by PARACEST MRI: a general approach to target a large variety of enzymes. Angew Chem Int Ed Engl 2008;47:4370-72
76. Raghunand N, Gatenby RA, Gillies RJ. Microenvironmental and cellular consequences of altered blood flow in tumours. Br J Radiol 2003;76:S11-S22
77. Rofstad EK. Microenvironment-induced cancer metastasis. Int J Radiat Biol 2000;76:589-605
78. Raghunand N, Gillies RJ. pH and drug resistance in tumors. Drug Resist Updat 2000;3:39-47
79. Matsumoto H, Inoue N, Takaoka H, et al. Depletion of antioxidants is associated with no-reflow phenomenon in acute myocardial infarction. Clin Cardiol 2004;27:466-70
80. Aime S, Botta M, Gianolio E, et al. A pO2-responsive MRI contrast agent based on the redox switch of manganese (II/III)-porphyrin complexes. Angew Chem Int Ed 2000;39:747-50
81. Raghunand N, Jagadish B, Trouard TP, et al. Redox-sensitive contrast agents for MRI based on reversible binding of thiols to serum albumin. Magn Reson Med 2006;55:1272-80
82. Ratnakar SJ, Woods M, Lubag AJ, et al. Modulation of water exchange in europium(III) DOTA-tetraamide complexes via electronic substituent effects. J Am Chem Soc 2008;130:6 -7. Epub 2007 Dec 8